• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by LianBio

    3/21/24 8:00:10 AM ET
    $LIAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIAN alert in real time by email
    15-12G 1 lianbio-form15.htm 15-12G Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 15
    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Commission File Number 001-40947
    LianBio
    (Exact name of registrant as specified in its charter)
    103 Carnegie Center Drive, Suite 309
    Princeton, NJ 08540
    (609) 486-2308
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
    American Depositary Shares, each representing one ordinary share, par value $0.000017100448 per share
    (Title of each class of securities covered by this Form)
    None
    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
    Rule 12g-4(a)(1)
    ☒
    Rule 12g-4(a)(2)
    ☐
    Rule 12h-3(b)(1)(i)
    ☒
    Rule 12h-3(b)(1)(ii)
    ☐
    Rule 15d-6
    ☐
    Rule 15d-22(b)
    ☐
    Approximate number of holders of record as of the certification or notice date: 14.
    Pursuant to the requirements of the Securities Exchange Act of 1934, LianBio has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
    Date: March 21, 2024By:/s/ Adam Stone
    Name: Adam Stone
    Title: Interim Chief Executive Officer

    Get the next $LIAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LIAN

    DatePrice TargetRatingAnalyst
    1/3/2024$5.00 → $3.00Buy → Underperform
    BofA Securities
    12/22/2023$7.00 → $4.00Buy → Hold
    Jefferies
    More analyst ratings

    $LIAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

      ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

      11/24/24 7:27:00 PM ET
      $LIAN
      $MGTX
      $OLMA
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LianBio Announces Voluntarily Delisting from Nasdaq

      SHANGHAI, China and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that it has provided notification to The Nasdaq Stock Market, Inc. ("Nasdaq") of its intent to delist the Company's American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share of the Company, from the Nasdaq Global Market. LianBio expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its

      2/28/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio Announces Completion of Strategic Review

      SHANGHAI, China and PRINCETON, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- LianBio (NASDAQ:LIAN) ("LianBio" or the "Company"), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company's Board of Directors (the "Board") had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares ("ADSs"), each representing the right to receive one ordinary share, from the Nasdaq Global Market ("Nasdaq") and deregistration under Section 12(b) of the Securities

      2/13/24 7:00:00 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LianBio downgraded by BofA Securities with a new price target

      BofA Securities downgraded LianBio from Buy to Underperform and set a new price target of $3.00 from $5.00 previously

      1/3/24 7:58:41 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LianBio downgraded by Jefferies with a new price target

      Jefferies downgraded LianBio from Buy to Hold and set a new price target of $4.00 from $7.00 previously

      12/22/23 7:26:46 AM ET
      $LIAN
      Biotechnology: Pharmaceutical Preparations
      Health Care